Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTPI for Behavioral and Psychological Symptoms of Alzheimer's Disease (Phase II, Japan)
jRCT2071220042Phase 2Active, not recruiting
- Sponsor
- Nippon Zoki Pharmaceutical
- Start
- Oct 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of neurotropin in Alzheimer's disease (AD) (3 arms), sponsored by Nippon Zoki Pharmaceutical. Started Oct 2022; status: active, not recruiting.
02
Drugs
neurotropin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2071220042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220042.